|
| |
Pharmasset, Inc.We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of human immunodeficiency virus, or HIV, hepatitis B virus, or HBV, and hepatitis C virus, or HCV. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication.
| Contact Details: |
| 303-A College Road East |
| Princeton |
| New Jersey |
| 08540 |
| United States of America |
| Tel: | (609) 613-4100 |
| Fax: | (609) 613-4150 |
| Email: | info@pharmasset.com |
| WWW: | www.pharmasset.com/
|
|
Loading...
|
Press Releases on Pharmasset, Inc.:
|
 |
| Pharmasset Reports Fiscal Year End 2009 Financial Results |
25th November, 2009 |
Pharmasset, Inc. |
PRINCETON, N.J., Nov. 25 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to
|
| Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C |
23rd November, 2009 |
Pharmasset, Inc. |
Contact
Richard E. T. Smith, Ph.D.
VP, Investor Relations and Corporate Communications
richard.smith@pharmasset.com
Office: +1 (609) 613-4181
Forward-Looking Statements
Pharmasset "Safe
|
| Pharmasset to Present at Lazard Capital Markets Healthcare Conference |
9th November, 2009 |
Pharmasset, Inc. |
PRINCETON, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Sixth Annual Lazard Capital Markets Healthcare Conference. The conference
|
| INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227 |
3rd November, 2009 |
Pharmasset, Inc. |
BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- Pharmasset, Inc (Nasdaq: VRUS) and InterMune, Inc. (Nasdaq: ITMN) today announced results from all patient cohorts of the INFORM-1 trial, an innovative Phase 1
|
| Pharmasset Nominates PSI-879 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development |
6th October, 2009 |
Pharmasset, Inc. |
PRINCETON, N.J., Oct. 6 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the nomination of PSI-352879 (PSI-879) as a second development candidate from two series of purine
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 265 times since April 2007, the link to the organisation's website has been followed 40 times Search for more companies in Princeton Search for more companies in New Jersey This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Pharmasset, Inc. |
